` LYRA (Lyra Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

LYRA
vs
S&P 500

Over the past 12 months, LYRA has underperformed S&P 500, delivering a return of -21% compared to the S&P 500's 10% growth.

Stocks Performance
LYRA vs S&P 500

Loading
LYRA
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
LYRA vs S&P 500

Loading
LYRA
S&P 500
Difference
www.alphaspread.com

Performance By Year
LYRA vs S&P 500

Loading
LYRA
S&P 500
Add Stock

Competitors Performance
Lyra Therapeutics Inc vs Peers

S&P 500
LYRA
LLY
JNJ
NOVO B
ROG
Add Stock

Lyra Therapeutics Inc
Glance View

Market Cap
13.8m USD
Industry
Pharmaceuticals

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-05-01. The firm is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.

LYRA Intrinsic Value
51.69 USD
Undervaluation 80%
Intrinsic Value
Price
Back to Top